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Abstract 
 
In severe pneumonias, including Coronavirus disease 2019 (COVID-19), the viral replication           
phase is often followed by a hyperinflammatory reaction (‘cytokine storm syndrome’) that leads             
to acute respiratory distress syndrome and death, despite maximal supportive care. Preventing            
hyperinflammation is key to avoiding these outcomes. We previously demonstrated that alpha-1            
adrenergic receptor antagonists (​⍺​-blockers) can prevent cytokine storm syndrome and death in            
mice. Here, we conduct a retrospective analysis of patients with acute respiratory distress (n =               
13,125) or pneumonia (n = 108,956) from all causes; patients who were incidentally taking              
⍺​-blockers had a reduced risk of requiring ventilation (by 35% and 16%, respectively), and a               
reduced risk of being ventilated and dying (by 56% and 20%, respectively), compared to              
non-users. Beta-adrenergic receptor antagonists had no significant effects. These results          
highlight the urgent need for prospective trials testing whether prophylactic ​⍺​-blockers improve            
outcomes in diseases with a prominent hyperinflammatory component such as COVID-19. 
 
 
 
 
  
 
1 
 
  
 
 
Introduction 
Each year ~300 million people contract bacterial or viral pneumonia ​[1]​, which is usually              
overcome by a local immune/inflammatory response. In severe cases (Figure 1A), the pathogen             
overwhelms host defenses, causing massive lung damage and compromising other organs. In            
some patients, pathological immune activation (‘hyperinflammation') occurs in the lungs and           
systemically. Infection and immune-mediated damage can compromise gas exchange, leading          
to acute respiratory distress syndrome (ARDS) and the need for mechanical ventilation; other             
organ systems may also fail. Dysregulated immune responses contribute substantially to the            
global pneumonia death toll of 3 million per year ​[2]​. The clinical picture is similar in Coronavirus                 
disease 2019 (COVID-19) caused by SARS-CoV-2, including hyperinflammation in the lungs           
and other organs, ultimately compromising function and causing high morbidity and mortality            
[3–6]​.  
Disease-modifying strategies for these conditions include targeting the virus, such as           
with antivirals, and preventing hyperinflammation with immunomodulators or        
immunosuppressors. Here, we propose an approach using the latter strategy of           
hyperinflammation prevention. Specialized cells of the immune/inflammatory response        
communicate with each other by secreting peptides called cytokines, which amplify the            
response and restore homeostasis after the threat has receded. However, in hyperinflammation,            
cytokines and other molecules trigger immune cells to produce even more cytokines, forming a              
‘cytokine storm’ that can damage healthy tissue and overwhelm the host. Some patients with              
COVID-19 experience cytokine storm syndrome (CSS), which is characterized by elevated           
pro-inflammatory cytokines, including interleukin (IL)-6, IL-2R, tumor necrosis factor-α, and          
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granulocyte-colony stimulating factor, among others ​[4,6–10]​. One proposed        
immunosuppressive approach to ameliorating CSS is blocking IL-6 signaling. IL-6 levels predict            
COVID-19 severity and in-hospital mortality ​[3,10,11]​; monoclonal antibodies against IL-6          
(siltuximab) and its receptor (tocilizumab and sarilumab) are in clinical trials for            
COVID-19-induced CSS ​[12–23]​. However, the utility of antibodies is likely to be restricted by              
their prohibitive costs and the risks of suppressing antiviral host responses, which include             
prolonged immunosuppression and potential adverse reactions. 
Another potential target for preventing hyperinflammation is the catecholamine system.          
Catecholamine release precedes hyperinflammation and enhances inflammatory injury by         
augmenting cytokine production via a self-amplifying process that requires alpha-1 adrenergic           
receptor (​⍺​1​-AR) signaling ​[24]​. In mice, catecholamine synthesis inhibition reduced cytokine           
responses and increased survival after inflammatory stimuli. The ​⍺​1​-AR antagonist prazosin (at            
clinically realistic dosages)—but not beta-adrenergic receptor (β-AR) antagonists—offered        
similar protection, showing that this drug class can prevent cytokine storm syndrome ​[24]​. These              
preclinical findings provide a rationale for clinical studies that assess whether ​⍺​1​-AR antagonists             
can prevent CSS and its sequelae. 
 
Methods and Results 
To date, no controlled trials have studied whether ​⍺​1​-AR antagonism reduces CSS, ARDS, or              
mortality in patients with acute respiratory distress or pneumonia. We therefore conducted a             
retrospective analysis of two cohorts of hospitalized patients from the MarketScan Research            
Database (2007-2015). Some patients were taking ​⍺​1​-AR antagonists (doxazosin, alfuzosin,          
prazosin, silodosin, terazosin, or tamsulosin) to treat chronic conditions unrelated to ARDS,            
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such as benign prostatic hyperplasia (BPH), hypertension, or post-traumatic stress disorder           
(PTSD). A medication was considered to be in active use on the admission date if the drug’s                 
medication possession ratio was ≥50% in the year prior to the admission. Due to transitions to                
Medicare coverage at age 65, and because over 90% of ​⍺​1​-AR antagonist users are male (due                
to BPH), we studied 45- to 64-year-old men. We estimated odds ratios (OR) and adjusted odds                
ratios (AOR) using logistic regression to relate receipt of ​⍺​1​-AR antagonists to two outcome              
measures: progression to mechanical ventilation and further progression to in-hospital death.           
We used profile maximum likelihood to estimate confidence intervals (CI) ​[25]​. ​Reported            
p​-values use a one-sided Wald statistic test with the alternative hypothesis that the treatment              
reduces risk. Models were adjusted for age, fiscal year, prior inpatient admissions, total prior              
days as an inpatient, and comorbidities identified from healthcare encounters in the prior year:              
hypertension, ischemic heart disease, acute myocardial infarction, heart failure, chronic          
obstructive pulmonary disease, diabetes mellitus, and PTSD.  
The first cohort comprised 13,125 patients diagnosed with acute respiratory distress           
(ICD-9 code 518.82), which is often a precursor to ARDS (Figure 1B). In this cohort, taking                
⍺​1​-AR antagonists, compared to non-users, was associated with a 22% lower incidence (relative             
risk reduction) of mechanical ventilation (p ≤ 0.009), and a 38% lower incidence of ventilation               
and death (p ≤ 0.023). We next specifically assessed the most commonly used ​⍺​1​-AR              
antagonist, tamsulosin, which is selective for ​⍺​1A and ​⍺​1D receptor subtypes. Tamsulosin is used              
almost exclusively for BPH, thus reducing the likelihood of confounding by indication. Acute             
respiratory distress patients taking tamsulosin had a 35% lower incidence of mechanical            
ventilation and a 55% lower incidence of ventilation and death (p ≤ 0.002 and p ≤ 0.015,                 
respectively). In contrast, β-AR antagonist use did not affect either clinical outcome.  
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Figure 1​. (​A​) Model of clinical progression of COVID-19 from local infection to systemic              
hyperinflammation (“cytokine storm”). The timing and relation of hyperinflammation to specific           
organ manifestations of severe COVID-19 are areas of uncertainty and investigation. (​B​)            
Patients from MarketScan Research Database with acute respiratory distress. (B.i) For those            
who required ventilation: (left) number and proportion of patients taking medications, (right)            
odds ratios and confidence intervals (unadjusted and adjusted) and p-values. (B.ii) Same for             
those who experienced ventilation and death. (​C​) Same as (B) but for those patients with               
pneumonia (AHRQ category code). The results from (B) and (C) are qualitatively similar: ​⍺​1​-AR              
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antagonist users, and specifically tamsulosin users, have a significantly reduced likelihood of            
progression to death, whereas β-AR antagonists have no meaningful impact.  
 
The second cohort was 108,956 patients diagnosed with pneumonia, identified by the            
Agency for Healthcare Research and Quality’s (AHRQ) pneumonia category (Figure 1C). We            
found that taking ​⍺​1​-AR antagonists, compared to non-users, was associated with a 13% lower              
incidence of mechanical ventilation (p ≤ 0.001), and a 16% lower incidence of ventilation and               
death (p ≤ 0.040). Pneumonia patients taking tamsulosin specifically had a 16% lower incidence              
of mechanical ventilation compared to non-users (no ​⍺​1​-AR antagonist), and a 20% lower             
incidence of ventilation and death (p ≤ 0.001 and p ≤ 0.042, respectively). As above, β-AR                
antagonist use did not affect either clinical outcome. 
All stated results were robust to multiple propensity weighting approaches and doubly            
robust methods such as causal forests ​[26,27]​.  
 
Discussion 
The results of this retrospective clinical study extend preclinical findings to support the             
hypothesis that ​⍺​1​-AR antagonists may reduce morbidity and mortality in patients at risk for              
developing cytokine storm syndrome ​[28]​. Randomized prospective trials will be needed to            
further test this hypothesis, specifically in patients at risk of cytokine storm due to COVID-19. In                
such trials, early administration of ​⍺​1​-AR antagonists prior to development of severe symptoms             
is required because the goal is to prevent, rather than treat, hyperinflammation.  
⍺​1​-AR antagonists with various receptor subtype specificities have been used to treat            
millions of patients with benign prostatic hyperplasia, hypertension, and other disorders. This            
history supports their safety profile ​[29]​, although caution is warranted in using any medication              
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for the first time in a new disease such as COVID-19. Given the poorly understood relationship                
between COVID-19 and hypertension ​[28]​, it is important to note that non-receptor-subtype            
selective (​⍺​1A​=​⍺​1B​=​⍺​1D​) ​⍺​1​-ARs, such as prazosin, are used to reduce blood pressure, whereas             
receptor-subtype selective drugs such as tamsulosin (​⍺​1A​=​⍺​1D​>​⍺​1B​) have fewer hemodynamic          
effects. 
⍺​1​-AR antagonists are inexpensive and administered orally, enabling widespread use if           
prospective trials support their efficacy and safety. Beyond COVID-19 and other pneumonias,            
⍺​1​-AR antagonists may also reduce cytokine storms and their sequelae in adoptive cell therapy              
and autoimmune rheumatic disease. 
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